BAFF / APRIL
Assets acting on this target.
- Class
- Fusion protein (TACI-Fc, dual BAFF/APRIL inhibitor)
- Pathway
- B-cell survival signaling (BAFF/APRIL pathway)
BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) are signaling proteins belonging to the tumor necrosis factor family that support the survival, maturation, and antibody production of B lymphocytes, the immune cells responsible for producing antibodies. In autoimmune diseases, excessive BAFF/APRIL signaling can sustain self-reactive B cells and the plasma cells that secrete harmful autoantibodies, contributing to tissue damage. TACI-Fc is a fusion protein built from the extracellular portion of TACI, a natural receptor for both BAFF and APRIL, joined to an antibody fragment; it works as a decoy that binds and neutralizes both cytokines before they can engage their receptors on B cells. Targeting both ligands simultaneously, rather than BAFF alone, is intended to suppress a broader range of B-cell and plasma-cell populations, since some long-lived antibody-secreting plasma cells depend more heavily on APRIL than on BAFF for survival. This dual blockade is being explored across autoimmune and inflammatory conditions in which B-cell-driven autoantibody production plays a central role, including lupus and certain kidney and rheumatologic diseases. Because B cells and plasma cells are also essential for normal immune defense, modulating this pathway carries an inherent balance between reducing autoimmune activity and preserving protective antibody responses.
By indication
Related mechanisms
BAFF / APRIL drugs compared
3 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Povetacicept | Vertex Pharmaceuticals | fusion protein | Phase 3 | Phase 3 in IgA Nephropathy; Phase 2/3 in Primary Membranous Nephropathy; Phase 2 in Myasthenia Gravis |
| Telitacicept | RemeGen Co., Ltd., Vor Bio | fusion protein | Phase 3 | Phase 3 in Generalized Myasthenia Gravis; Phase 3 in IgA Nephropathy; Phase 3 in Rheumatoid Arthritis; Phase 3 in Sjögren's Disease |
| aritinercept | Aurinia Pharmaceuticals | recombinant protein | Phase 1/2 | Phase 1/2 in Generalized Myasthenia Gravis |